Gamesinvestor1
31 Jul 2018
Is there any point in hanging on to this, or just take the money before it’s all diluted away? The company is still burning cash at an enormous rate (correct me if that’s wrong) and now that it’s core proposition on allergies has been blown out of the water - is it just going to wither and die, with many cost cutting exercises before the lights are switched off? Games
Ripley94
25 Jul 2018
Limit buy yesterday CIR… XXXXX You can pick them up for 75p now.
gamesinvestor
24 Apr 2018
AZN ups stake [link]
gamesinvestor
27 Dec 2017
Woodford adds more [link]
gamesinvestor
29 Nov 2017
NICE [link] UK - 29 November 2017: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, welcomes the publication of new clinical guidelines by the UK's National Institute for Health and Care Excellence (NICE), which recommend the use of fractional exhaled nitric oxide (FeNO) testing as part of asthma diagnosis. Circassia's NIOX® products are novel point-of-care FeNO measurement devices, which are available in many countries across Europe, including the UK, as well as the United States, China, Japan and a range of other territories.Games
sage in the hills
17 Oct 2017
RNS Morgan Stanley ....have increased their holdings in CircassiaSAGE
itssoconfusing
25 Sep 2017
Re: Woodford guysPicked up a few here (for the first time).With something that works and a story things should (very) slowly look better for CIR.Let's hope the results and more importantly investors presentation get some traction.There again....itsso...
Ripley94
07 Sep 2017
Re: Woodford On Wednesday i was pleased to find after buying that i had in fact sold my first purchase.I'm not pleased now lol ... what a difference a day makes as the song goes.
sage in the hills
07 Sep 2017
RNS Circassia Announces Duaklir® Successfully Met Primary Endpoints in AMPLIFY Phase III Study in Chronic Obstructive Pulmonary DiseaseØ NDA submission planned H1 2018 by partner AstraZenecaØ Filing supported by positive results from ACHIEVE dose-ranging studyØ Circassia has exclusive commercialisation rights to Duaklir® in the United States Oxford, UK - 7 September 2017: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces positive top-line results from the AMPLIFY phase III study of Duaklir®* in chronic obstructive pulmonary disease (COPD), which was conducted by the Company's partner AstraZeneca. Duaklir® is a fixed-dose combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and long-acting beta-agonist (LABA) formoterol fumarate, administered via the Pressair®** inhaler. The AMPLIFY study met its co-primary efficacy endpoints with Duaklir® demonstrating statistically significant and clinically meaningfully improvements in lung function, measured by forced expiratory volume in one second (FEV1), compared with the combination's individual component monotherapies (aclidinium and formoterol). Aclidinium monotherapy (Tudorza®*** Pressair®
also achieved its primary bronchodilation endpoint demonstrating non-inferiority to tiotropium (Spiriva® Handihaler®. Additionally, a sub-study of 24-hour bronchodilation demonstrated statistically significant greater night-time bronchodilation for twice-daily Duaklir® and Tudorza® compared to once-daily Spiriva®. The safety profiles of Duaklir® and its individual components were consistent with previous studies. A full evaluation of the AMPLIFY data is ongoing and the results will be submitted for presentation at a forthcoming medical meeting. Next stepsUnder the April 2017 collaboration established between Circassia and AstraZeneca, Circassia has exclusive commercialisation rights to Duaklir® in the United States and AstraZeneca is responsible for conducting the product's development. Circassia also has responsibility for marketing Tudorza® in the United States. Following the completion of the AMPLIFY study, AstraZeneca plans to file a New Drug Application (NDA) for Duaklir® with the United States Food and Drug Administration (FDA) during the first half of 2018. In addition to AMPLIFY's positive clinical results, AstraZeneca and Circassia believe the study trial materials' in vitro comparability data also meet FDA requirements. The Duaklir® NDA will include results from the recently-completed ACHIEVE dose-ranging study. This compared the bronchodilation effects of three doses of formoterol delivered twice daily via Pressair® (6 µg, 12 µg and 24 µg) with nebulised formoterol (Perforomist® inhalation solution 20 µg twice daily). The study's results support the 12 µg dose of formoterol included in the AMPLIFY study as the optimal dose for inhalation via Pressair®. As part of the regulatory process, AstraZeneca intends to seek a pre-NDA meeting with the FDA in the coming months. Steve Harris, Circassia's Chief Executive, said: "We are delighted with these positive phase III results and believe Duaklir® has the potential to provide a valuable treatment option for COPD patients in the United States. With treatment guidelines now placing a greater emphasis on LAMA / LABA combinations, we look forward to our partner AstraZeneca filing an NDA for Duaklir® in the coming months." Steve Lewington, Global Medicine Leader, Respiratory, AstraZeneca said: "The AMPLIFY study top-line results provide further clinical evidence of Duaklir®'s efficacy and support making this LAMA / LABA combination treatment option available to COPD patients in the US." About AMPLIFYAMPLIFY was a randomised, parallel-group, double-blind, multinational phase III study. It enrolled over 1,500 patients with stable COPD in the United States, United Kingdo
sage in the hills
07 Sep 2017
Numis 180p Broker Forecast - Numis issues a broker note on Circassia Pharmaceuticals PlcStockMarketWire | Thu, 7th September 2017 - 10:10Numis today reaffirms its buy investment rating on Circassia Pharmaceuticals Plc (LON:CIR) and set its price target at 180p.SAGE
Ripley94
07 Sep 2017
Re: Limit buy yesterday That was a lucky buy yesterday I'm not sure i should adapt how i pick em !!!Wonder what the chart looks like.Appears to be up 13%.Maybe there is a God and he approved of me ringing up LBC and speaking to nick F in support of Ress-mogginstead of checking shares between 8 and 9 .. lol
Ripley94
06 Sep 2017
Re: Woodford Today... 8/11/16... 25/04/16... 13/03/16.. Just seen that i sold the first buy on 29/06/16 @ 97pThat was lucky 
only noticed as i added today's buy to record.
Ripley94
06 Sep 2017
Re: Limit buy yesterday Topped up @ 80p... again i can see it a little lower @ after an hour.
IAmShareCrazy
25 Aug 2017
Re: I don't BELIEEEEVE it! I opened up a short today. This doesn't sound like a promising business at all! Director sales, heavy volume sell a few weeks back and failure of their main products. Thanks for the insight!
LK Hyman
06 Jun 2017
I don't BELIEEEEVE it! A CIR non exec, name of Jean Jacques Crapaud or some such, exercises 77,000 options which were effectively free ... total bill £60 odd ... and promptly turns around and sells the whole lot for £60,000 odd. That's a THOUSAND BAGGER for the Frenchy ... in a single day ffs.It's a goddamn scandal, shipm8es, no word of a lie!Quite apart from the total iniquity of giving a NED virtually free options, what kind of a signal does it send to the market about the wretched feller's views about CIR's prospects, eh?No wonder this terminal munter has tanked another 4% today!What does Woody have to say about this egregious failure in corporate governance ... assuming the crop-haired thug isn't spending all his time bemoaning the further fall in his Allied Minds shares as well as in this munter?Why oh why did I EVER pay ANY heed to what Woody was investing in? He's clearly lost it ... big time.LKH at the LK Wash & Valet at least my Treatt shares are doing well
